rxstat › Shortages › Aflibercept

Aflibercept shortage status

No current shortage

Source: Health Canada shortage reports · Updated Jul 9, 2026

Aflibercept has no current shortage reported in Canada. It has been in shortage before; the history is below.
Products affected
0 / 3
Reports on file
3

Reports by product

Resolved
YESAFILI
2MG · SOLUTION · BIOSIMILAR COLLABORATIONS IRELAND LIMITED
DIN 02558238 · ended Mar 16, 2026 · Other (Please describe in comments)
Discontinued
ZALTRAP
200MG · SOLUTION · SANOFI-AVENTIS CANADA INC
DIN 02421089
Discontinued
ZALTRAP
100MG · SOLUTION · SANOFI-AVENTIS CANADA INC
DIN 02421070

What's happening

There are no active shortage reports for Aflibercept. Health Canada has 3 historical reports on file for this drug, so supply has been disrupted before; the change log below shows the history.

Aflibercept is classified under “OCULAR VASCULAR DISORDER AGENTS” (ATC S01LA).

Recent changes

Common questions

When will Aflibercept be back in stock in Canada?

Aflibercept has no active shortage; supply is normal per Health Canada reports.

Why is Aflibercept in shortage?

It isn't currently. Past reports and their reasons are listed above.

What can my pharmacist do about it?

Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.

Related drugs (ocular vascular disorder agents)

Widespread shortageVerteporfin1 of 1 reported products affected · est. return Dec 31, 2026Partial shortageRanibizumab1 of 1 reported products affected · est. return Jun 30, 2027No current shortageBrolucizumab

Guides: what to do when your medication is in shortage · how to read shortage reports

Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.